Officials from the National Institute for Health and Care Excellence (Nice) have made a preliminary decision not to recommend covering the drug radium-223 dichloride (Xofigo) for use for men with prostate cancer that has spread to the bone. This latest draft guidance from Nice states that Bayer has not provided information on how Xofigo performs [...]
Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec, Canada now have access to Zytiga (abiraterone acetate) prior to having chemotherapy. Effective February 3, 2014, the province has added ZYTIGA to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT). [...]
Now that Radium-223 Dichloride (Xofigo) has been approved by the FDA for use in men with castrate resistant prostate cancer with bone metastases we will begin to see the actual treatments happening. The next question in the process that will arise is whether or not it is safe and effective to re-treat an individual with [...]
We are in the fortunate position because the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) continues to evolve as new agents with the ability to extend survival gain FDA approval. The most recently FDA approved treatment, the alpha emitting radiopharmaceutical radium-223 (Xofigo) was approved for men with bone metastatic prostate cancer. Most other [...]
The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels
Most of the newly approved drugs and treatments for men with advanced prostate cancer are designed and approved to be used independently of other advanced prostate cancer treatments, other than with the continuation of standard androgen deprivation therapy (ADT). The newly approved drug, Xofigo, is different. It has been designed to supplement, or actually go [...]
The following post is actually a response to a listserve issue over the side effects of Xofigo. I decided to post my response here to avoid the limit of lines allowed on the listserve and because I feel that it is also of interest to my regular readers of this blog. My response is using [...]
The New England Journal of Medicine just published a very appealing and easy to understand video about Xofigo dichloride (Radium 223 or Alpharadin), the newly FDA approved treatment for men with advanced prostate cancer who have developed bone metastasis. The short video can be viewed at: N.E. Journal Xofigo Video Joel T. Nowak, M.A., M.S.W.
In an interview about radium 223 with Medscape Medical News, Dr. Vapiwala pointed out that radium-223 is the first alpha-emitter to reach the market, and described it as a "breakthrough for radiopharmaceuticals" and "another breakthrough for prostate cancer," as it joins several other agents that have recently been approved for this disease. She characterized the [...]
The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]
